Later studies highlighted a potential application of this molecule to inhibit HO in FOP, by directly targeting endochondral ossification and SMAD1/5 expression [144,145], which led to the initiation of clinical trials in FOP. The gene discussed is SMAD1; the disease is fibrodysplasia ossificans progressiva.